Join
Live feed
·
INSIDERFilingvia Quantisnow
Neoleukin Therapeutics Inc. logo

SEC Form 4: Drachman Jonathan G bought $933,550 worth of Common Stock (150,000 units at $6.22), increasing direct ownership by 4% to 2,348,686 units

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NLTX (Neoleukin Therapeutics Inc.) and more on Quantisnow.